$AMGN 0.55 Developing

Notable posts

• @TrendSpider neutral 97 eng

  Here is every stock in the S&P 500 $SPY making new all-time highs today 👀 Expedia Group $EXPE Amgen $AMGN Charles Schwab $SCHW Freeport-McMoRan $FCX Coca-Cola $KO Labcorp $LH Quest Diagnostics $DGX Valero Energy $VLO https://t.co/Z3LWrdvHE0

  view on X →
• @wallstengine bullish 35 eng

  $AMGN PHASE 3 SJÖGREN’S TRIAL HITS PRIMARY ENDPOINT Amgen says dazodalibep significantly improved systemic disease activity in patients with moderate-to-severe Sjögren’s disease, with benefits seen as early as Week 4 and sustained through Week 48. The Phase 3 OASIZ 301 trial enrolled about 621 patients and met its primary endpoint based on the ESSDAI disease activity score. There are currently no FDA-approved medicines for Sjögren’s disease. A second Phase 3 study, OASIZ 303, focused on symptomatic Sjögren’s, is expected to complete in Q4.

  view on X →